Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications

Front Matter ....Pages i-xxv
Front Matter ....Pages 1-1
 The distribution and biochemistry of 5-hydroxytryptamine in the cardiovascular system  (Tony J. Verbeuren)....Pages 3-13
 5-Hydroxytryptamine transport systems  (David Graham, Salomon Z. Langer)....Pages 15-30
 Cloning of the choroid plexus 5-HT1C receptor  (Paul R. Hartig)....Pages 31-39
 Regional differences in the transduction mechanisms of 5-hydroxytryptamine receptors in the mammalian brain  (M. Hamon, M. B. Emerit, S. el Mestikawy, M. C. Gallissot, H. Gozlan)....Pages 41-59
 Reduction of a distinct pool of monoamines by ketanserin in peripheral tissues  (J. E. Leysen, J. Wynants, A. Eens, P. A. J. Janssen)....Pages 61-66
Front Matter ....Pages 67-67
 Putative agonists and antagonists at 5-HT1-like receptors  (Wasyl Feniuk, Patrick P. A. Humphrey)....Pages 69-80
 Agonists and antagonists of 5-HT2 receptors  (E. J. Mylecharane)....Pages 81-100
 Agonists and antagonists of 5-HT3 receptors  (John R. Fozard)....Pages 101-115
 The continuing story of 5-hydroxytryptamine receptors: a 5-HT3 receptor modulates dopamine release from rat striatal slice  (Patrizio Blandina, Joseph Goldfarb, Jack Peter Green)....Pages 117-126
 Allosteric modulation of arterial 5-HT2 receptors  (A. J. Kaumann, A. M. Brown)....Pages 127-142
 An analysis of unsurmountable antagonism to 5-hydroxytryptamine in the isolated perfused rat kidney: evidence for pseudoirreversible inhibition  (D. A. Craig, A. G. Ornstein, D. E. Clarke)....Pages 143-155
 Tryptamine fingerprints in the classification of 5-hydroxytryptamine receptors  (G. R. Martin, P. Leff, S. J. Maclennan)....Pages 157-162
Front Matter ....Pages 163-163
 Central neuronal responses and 5-hydroxytryptamine receptors  (M. H. T. Roberts, M. Davies)....Pages 165-176
 5-Hydroxytryptamine and related drugs and autonomic ganglia  (D. I. Wallis, P. Elliott)....Pages 177-190
 5-Hydroxytryptaminergic neurotransmission in the gut  (Michael D. Gershon, Gary M. Mawe, Theresa A. Branchek)....Pages 191-210
 Presence of 5-hydroxytryptamine in adrenergic nerves of the brain circulation: its role in sympathetic neurotransmission and regulation of the cerebral vessel wall  (Christer Owman, Jing-Yu Chang, Jan Erik Hardebo)....Pages 211-230
Front Matter ....Pages 231-231
 Cardiovascular reflexes and 5-hydroxytryptamine  (Daniel S. McQueen)....Pages 233-245
 Central 5-hydroxytryptamine (5-HT) and its effect on the cardiovascular system  (A. K. Mir, J. R. Fozard)....Pages 247-258
 The central antihypertensive action of 5-hydroxytryptamine: The location of site of action  (J. H. Coote)....Pages 259-270
 The role of 5-hydroxytryptamine in the regulation of sympathetic nerve discharge  (Robert B. McCall)....Pages 271-283
 5-Hydroxytryptamine and related drugs and transmitter release from autonomic nerves in the cardiovascular system  (M. Göthert, K. Fink, G. Molderings, E. Schlicker)....Pages 285-294
 Receptors for 5-hydroxytryptamine in the cardiovascular system  (Marlene L. Cohen)....Pages 295-302
 Altered responses to 5-hydroxytryptamine in hypertension and other cardiovascular disorders  (J. M. Van Nueten, W. J. Janssens, P. A. J. Janssen)....Pages 303-310
 5-Hydroxytryptamine receptor antagonists as antihypertensive drugs  (Pramod R. Saxena)....Pages 311-318
 Ketanserin in hypertension and vasospastic disease: mechanism of action  (Maarten A. D. H. Schalekamp, Gert-Jan Wenting)....Pages 319-327
 Renin secretion and 5-hydroxytryptamine  (William F. Ganong)....Pages 329-337
 Acute and long-term effects of 5-hydroxytryptamine in isolated renal arteries in vitro  (J. G. R. de Mey, M. P. Uitendaal, H. C. M. Boonen, M. J. J. F. Vrijdag)....Pages 339-342
 Ventrolateral medullary pressor area: site of hypotensive and sympatho-inhibitory effects of (±) 8-OH-DPAT in anaesthetized dogs  (Michel Laubie, Madeleine Drouillat, Hubert Dabiré, Claudie Cherqui, Henri Schmitt)....Pages 343-346
 Evidence that spiperone reverses the additional sympathoinhibitory action of urapidil in anaesthetised, prazosin-pretreated cats  (Andrew G. Ramage)....Pages 347-350
 The effects of intrathecal ketanserin and phentolamine on heart rate and arterial blood pressure in the rat  (K. Mohan Dhasmana, Ajay K. Banerjee, Pramod R. Saxena)....Pages 351-354
 Early clinical experience with flesinoxan, a new selective 5-HT1A receptor agonist  (J. M. de Voogd, G. Prager)....Pages 355-359
Front Matter ....Pages 361-361
 Coronary circulation and 5-hydroxytryptamine  (James A. Angus, Archer Broughton, Thomas M. Cocks, Christine E. Wright)....Pages 365-378
 The endothelium and the role of 5-hydroxytryptamine in vascular disease  (Paul M. Vanhoutte)....Pages 379-389
 Vascular pharmacology of 5-hydroxytryptamine in humans  (Gerald J. Blauw, Peter Van Brummelen, Pieter A. Van Zwieten)....Pages 391-399
 Ketanserin in the treatment of septic shock  (Arend J. J. Woittiez, Jot Wolthuis, Leo Van Bergeijk)....Pages 401-404
Front Matter ....Pages 405-405
 5-Hydroxytryptamine and migraine  (Pramod R. Saxena)....Pages 407-416
 A rational approach to identifying a fundamentally new drug for the treatment of migraine  (P. P. A. Humphrey, E. Apperley, W. Feniuk, M. J. Perren)....Pages 417-431
 Treatment of migraine with drugs related to 5-hydroxytryptamine  (P. Tfelt-Hansen, T. H. Nielsen)....Pages 433-441
Front Matter ....Pages 443-443
 The human platelet 5-HT2-receptor: an up-date  (D. de Chaffoy de Courcelles, F. de Clerck)....Pages 445-457
 ICI 170809, A selective 5-hydroxytryptamine antagonist, inhibits human platelet aggregation in vitro and ex vivo  (Thomas P. Blackburn, Stephen J. Haworth, Carol L. Jessup, Pamela B. Morton, Christine Williams)....Pages 459-463
Back Matter ....Pages 465-471